The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2600 participants.
Also called NCT04728516
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 2,600 participants
- Registry
-
NCT04728516
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT04728516. Randomized; no masking; primary purpose prevention. Start 2023-04-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
- Condition
- Acute Coronary Syndrome
- Condition
- Helicobacter Pylori Infection
- Intervention (Drug)
- Vonoprazan-based dual eradication therapy for two weeks
- Intervention (Drug)
- amoxicillin
- Intervention (Drug)
- Pantoprazole
- Lead sponsor
- Qilu Hospital of Shandong University
Record details
- Record id
cardio:ct-nct04728516- Content hash
17fee9cd5c067757a8a2e864d72c9728242727e01ec37a2928f9b3eaa9b1bede